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Abstract
The mechanism by which pancreas secretes high HCO3
- has not been fully resolved. This
alkaline secretion, formed in pancreatic ducts, can be achieved by transporting HCO3
- from
serosa to mucosa or by moving H+ in the opposite direction. The aim of the present study
was to determine whether H+/K+-ATPases are expressed and functional in human pancre-
atic ducts and whether proton pump inhibitors (PPIs) have effect on those. Here we show
that the gastric HKα1 and HKβ subunits (ATP4A; ATP4B) and non-gastric HKα2 subunits
(ATP12A) of H+/K+-ATPases are expressed in human pancreatic cells. Pumps have similar
localizations in duct cell monolayers (Capan-1) and human pancreas, and notably the gas-
tric pumps are localized on the luminal membranes. In Capan-1 cells, PPIs inhibited recov-
ery of intracellular pH from acidosis. Furthermore, in rats treated with PPIs, pancreatic
secretion was inhibited but concentrations of major ions in secretion follow similar excretory
curves in control and PPI treated animals. In addition to HCO3
-, pancreas also secretes K+.
In conclusion, this study calls for a revision of the basic model for HCO3
- secretion. We pro-
pose that proton transport is driving secretion, and that in addition it may provide a protec-
tive pH buffer zone and K+ recirculation. Furthermore, it seems relevant to re-evaluate
whether PPIs should be used in treatment therapies where pancreatic functions are already
compromised.
Introduction
Digestive processes along the gastrointestinal tract are aided by acidic and basic secretions by a
number of epithelia. In particular, the pancreas and the stomach are the most avid base (HCO3
-)
and acid (H+) secretors, respectively. The gastric H+ secretory mechanisms are well established,
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however, the cellular mechanism by which pancreatic duct cells secrete almost isotonic HCO3
−
fluid has long been a challenge to epithelial physiologists.
The current ion transport model for pancreatic HCO3
− secretor, the duct cell, involves two
machineries on the two epithelial membranes: first, cells accumulate cellular HCO3
− with the
help of a basolateral Na+-HCO3
− cotransporter (pNBC, NBCe1) and a Na+/H+ exchanger
(NHE1) together with carbonic anhydrase; second, HCO3
− efflux occurs via co-operation be-
tween Cl− channels and Cl−/HCO3
− anion exchangers from the SLC26A6 family, e.g. SLC26A6
on the luminal membrane [1]. The Cl− channels are the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) Cl− channels, which may have some HCO3
− permeability [2,3] and the
Ca2+-activated Cl− channels, such as TMEM16A/ANO1 [4]. Furthermore, K+ channels (e.g.
KCa3.1, KCa1.1, KCNQ1) maintain the membrane potential and provide the driving force for
anion secretion together with the Na+/K+-ATPase [5–7]. Na+ and water follows passively. Nev-
ertheless, this model can only explain production of 80–100 mMNaHCO3 in secreted fluid, yet
human pancreas can secrete up to 140 mMNaHCO3. In addition to NBCs and NHE, earlier
studies have shown vacuolar H+ ATPase (V-ATPase) activity on the basolateral membrane of
pancreatic ducts by intracellular pH (pHi) measurements and use of the V-ATPase inhibitor
bafilomycin A1 [8–11] Nevertheless, whether the V-ATPase plays a significant role in pancreat-
ic HCO3
− secretion is not clarified, as for example in guinea pig pancreatic ducts bafilomycin
A1 could not inhibit agonist-stimulated HCO3
− and fluid secretion [12,13]. Therefore, in the
present study we have focused on the function of H+/K+-ATPases (pumps), which are pharma-
cologically approachable and physiologically relevant. Such H+/K+-pumps have not been pro-
posed for HCO3
− secreting tissues, except for our earlier study on rat pancreatic ducts [14];
rather they have well-established roles in acid secretion, and in H+ and K+ homeostasis in
other tissues.
The H+/K+-ATPases are classified into two subfamilies, gastric and non-gastric (latter also
called colonic), coded by ATP4A and ATP12A. The gastric H+/K+-ATPase is expressed in
stomach parietal cells, kidney distal nephrons [15–17] and cochlea [18,19], where they are re-
sponsible for H+ secretion, K+ absorption and K+ recirculation, respectively. The non-gastric
H+/K+-ATPase is present in several epithelial tissues including colon, kidney, skin, placenta,
and prostate, and here it is associated with acid-base or K+ and Na+ homeostasis [17,20–22].
Each pump is composed of two catalytic α-subunits and two regulatory β-subunits. The gastric
α-subunit (HKα1) assembles with the gastric β-subunit (HKβ), while the non-gastric α-subunit
(HKα2) can borrow the gastric β-subunit, and β3/β1-subunits of the Na+/K+-ATPase [20,23–
25]. The gastric H+/K+-ATPase is the primary target for treatment of peptic and duodenal ul-
cers and reflux diseases [26]. Proton pump inhibitors (PPIs), such as omeprazole, are activated
in acid environment of secretory canaliculus of the parietal cells and bind covalently to cyste-
ines of the ATPase [26]. Another experimental class of ATPase inhibitors are potassium-com-
petitive acid blockers (P-CABs), such as SCH28080, though at high concentrations they may
also inhibit the non-gastric H+/K+-ATPase [27,28].
Our hypothesis is that the H+/K+-ATPases may be important in supporting pancreatic func-
tion, which may be of particular relevance in human pancreas. In a most simplistic way, one
could envisage that these ATPases would pump H+ out towards the interstitium and provide
HCO3
- for luminal transport and thus fluid secretion.
Thus the aim of this study was to establish whether human pancreatic ducts express func-
tional gastric and/or non-gastric H+/K+-ATPase and whether H+/HCO3
- transport and whole
pancreatic secretion is sensitive to proton pump inhibitors (PPIs). For this purpose we have
used human cells/tissue and performed in vivo studies on the rat pancreas where H+/K+-
ATPases are expressed, as already established in our earlier study [14]. We show that human
duct cells express subunits of both gastric and non-gastric H+/K+-ATPases and these exhibit
H+/K+-ATPases in Pancreas
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unusual localization patterns. We propose that these pumps have physiological functions in
pancreatic H+/HCO3
- transport and fluid secretion, and speculate on their additional role in
mucosal protection and K+ recirculation. Most importantly, the present studies show that pro-
ton pump inhibitors inhibit pancreatic secretion and we speculate about consequences of using
these drugs as treatment therapies in several pancreatic diseases.
Materials and Methods
Ethical Approval
The permission for animal experiments and protocols were approved by the Danish Animal
Experimentation Inspectorate (license no. 2011/561-56 and 2012-15-2934-00693). The experi-
ments were performed on male Wistar rats weighing between 250 and 400 g. Data from 22 rats
treated with omeprazole, 6 rats treated with SCH28080, and 21 matched controls were included
in the study. For details see below.
Cell Culture
Pancreatic cell lines (human pancreatic ductal adenocarcinoma) were purchased from ATTC
(Manassas, VA, USA). PANC-1 (#CRL-1469) was grown in Dulbecco’s Modified Eagles Medi-
um (DMEM), CFPAC-1 (#CRL-1918) and Capan-1 (#HTB-79) were grown in Iscove’s Modi-
fied DMEM (IMDM). Cell culture media contained Glutamax, 10% (20% for Capan-1) fetal
bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin. Cells were grown at
37°C in a humidified atmosphere with 5% CO2. Cells from passage 12 to 25 were used in this
study. All standard chemicals were purchased from Sigma-Aldrich unless otherwise stated.
pHi Measurements
Methods for pHi measurements in Capan-1 cells are based on the one described elsewhere
[29]. Briefly, Capan-1 cells grown on standard Ibidi μ-Dish35mm were loaded with 2 μM
BCECF/AM (Invitrogen) for 20–30 min; thereafter they were superfused at 2 ml/min, at 37°C.
Control perfusate had the following composition (in mM): Na+ 145, Cl− 145, K+ 4, Ca2+ 1.5,
Mg2+ 1, phosphate 2, HEPES 10 glucose 5; pH was 7.4. For ammonium pulses 20 mMNa+ was
replaced with NH4
+. In Na+-free solutions, N-methyl-D-glucamine was used for replacement.
Intracellular pH (pHi) was estimated from changes in the fluorescence emission (at 510 nm)
from 15–20 cells after excitation at 495 and 440 nm. Signals for each batch of cells were cali-
brated in situ with 1 μM ionophore carbonyl cyanide m-chlorophenyl hydrazone, CCCP, and
the fluorescence ratios and pHi were fitted to a calibration curve. A standard method of ammo-
nium pre-pulse was used to study H+ transport. Tissues were exposed to ammonium pulses
(2–3 min), then ammonium was removed, and pHi recovery rates from acidosis were deter-
mined from the initial slopes of pHi changes and expressed as dpH/dt (i.e. pH units/min). The
following common representative acid blockers (PPIs and P-CABs) were used: omeprazole
(10 μM) and SCH-28080 (10 μM) (Sigma Aldrich). Acidified ethanol (0.15 M HCl in 75% etha-
nol) was used to prepare omeprazole stock solutions for these experiments, as omeprazole
needs acid environment to be activated.
Reverse transcription polymerase chain reaction (RT-PCR) and real-
time PCR
RT-PCR and real time PCR were carried out as detailed in our recent work [4]. Briefly, cells
were cultured to confluence and then RNA was isolated with RNeasy Mini Kit (Qiagen 74104).
DNase 1 (RNase free DNase Set, Qiagen 79254) was used to avoid any DNA contamination.
H+/K+-ATPases in Pancreas
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1 μg RNA per reaction was used in OneStep RT-PCR Kit (QIAGEN 210212) with amplification
parameters as follows: one cycle at 50°C for 30 min and one cycle at 95°C for 15 min followed
by 40 cycles at 95°C for 30 s, 55°C for 30 s, 72°C for 1 min, and finally, one cycle at 72°C for
10 min.
For real-time PCR, cDNA was synthesized based on 5 μg RNA template per reaction using
the RevertAid First Strand cDNA synthesis kit (Fermentas #K1622) with oligo (dT)18 primers
and RevertAid M-MuLV reverse transcriptase, and then purified using GenElute PCR Clean-
Up Kit (Sigma, NA1020). The purified cDNA was quantified by absorbance at 260/280 nm,
and 100 ng was used as template for each PCR reaction. The PCR reactions were run using
LightCycler 480 SYBR Green I Master (Roche, 04707516001) with parameters as follows: pre-
incubation for 5 min at 95°C followed by 45 amplification cycles of 10 s at 95°C, 1 min at 55°C,
and 30 s at 72°C. A melting curve was performed following the PCR by 5 s at 95°C, 1 min at
65°C, and subsequent heating up to 97°C, and then cooling down for 10 s at 40°C. Reactions
were performed as triplicates and were repeated four times. Table 1 shows primers used; these
were synthesized by MWGBiotech or TAG Copenhagen A/S (Copenhagen, Denmark). Four
house-keeping genes, 18S ribosomal RNA (18SrRNA), β-actin, β-glucuronidase (GUSB) and
glutaminyl-tRNA synthetase (QARS) were used for normalization. These genes have relatively
stable expression in both normal and cancerous pancreas [30].
Western Blot Analysis
Pancreatic cells, stomach and colon from mice were lysed by adding 5x diluted lysis buffer (50
mM Tris-base, 0.25 M NaCl, 10 mM EDTA, 0.5% NP40, 1% TritonX-100, 4 mM NaF, pH 7.5).
The final lysates were centrifuged at 15,000 g, 4°C for 15 min. Protein concentration was esti-
mated using Coomassie protein assay (Thermo Scientific). Mouse stomach and colon were
used as positive control. All solutions contained 1× Sigma protease inhibitor (Sigma S8820).
Protein samples were loaded on 10% polyacrylamide precast gels (Invitrogen), separated by
electrophoresis, and blotted to PVDF membranes (Invitrogen). Membranes were blocked with
5% skim milk solution in TBS-Tween (0.1%) buffer for 1 h at room temperature and incubated
overnight at 4°C with primary antibodies against gastric HKα1(1:1000 rabbit monoclonal,
Abcam, EPR12251 or polyclonal Calbiochem 119101), HKβ (1:1000 mouse monoclonal 2G11,
Table 1. Primer sets used for human pancreatic duct cell lines in RT-PCR and real-time analysis.
Primers Sequence Product length
HKα1 FW AAGATCTGCAGGACAGCTACGG 200
HKα1 RW CTGGAACACGATGGCGATCA
HKα2 FW CCCTGGGAGCTTTCCTTGTGTA 339
HKα2 RW TTCCGAGGCCATAGGAGAGGAT
HKβ FW GGCCTTCTACGTGGTGATGAC 136
HKβRW CCCGTAAACATCCGGCCTTA
18S rRNA FW TCGGAACTGAGGCCATGATT 150
18S rRNA RW CGAACCTCCGACTTTCGTTCT
β actin FW GTGACATTAAGGAGAAGCTGTGC 300
β actin RW CAATGCCAGGGTACATGGTG
GUSB FW ACTGACACCTCCAAGTATCCCA 200
GUSB RW AACAGGTTACTGCCCTTGACAG
QARS FW CCTCTATGAGCGACTATTCCAGC 200
QARS RW GATGGCTGTCTGGATCCACG
doi:10.1371/journal.pone.0126432.t001
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Sigma, A274), non-gastric HKα2 (1:1000 rabbit polyclonal, Sigma, HPA039526) or antibody
(C384-M79) [28], kindly donated by J. J. H. H. M. De Pont and H. G. P. Swarts, and β-Actin
(1:1000 mouse monoclonal C4, Santa Cruz, Sc-47778). Blots were then incubated with appro-
priate HRP-conjugated antibodies (DAKO or Santa Cruz), developed with EZ-ECL (Biological
Industries) and visualized on Fusion FX (Vilber Lourmat) and band intensity was calculated
using Bio1D software.
Immunocytochemistry
Human duct cells (Capan-1) were cultured to confluence on coverslips or Transwells (Costar,
3407), and then fixed in 4% paraformaldehyde for 15 min at room temperature. Human pan-
creatic sections (GeneTex) were deparaffinized according to standard procedures, and antigen
retrieval was performed with 1x citrate buffer in 98°C for 20 min. After washing with PBS,
monolayers or pancreatic sections were treated with 0.1 M TRIS-glycine (pH 7.4) for 15 min;
washed in phosphate buffered saline, PBS, with 0.3% TritonX-100 and blocked with 10% BSA
for 30 min. Subsequently, preparations were incubated with 1:50 to 1:300 dilutions of the pri-
mary antibodies recognizing the gastric HKα1, HKβ, or non-gastric HKα2 overnight at 4°C.
Then preparations were incubated with secondary antibodies conjugated to Alexa 568 or Alexa
488 (Invitrogen, 1:400). 4’, 6-diamidino-2-phenylindole (DAPI, 1:400) was used for nuclear
staining, and a fluorescent dye Texas Red-X phalloidin (Invitrogen; 1:40) was used for actin
staining. Fluorescence was examined with 40x 1.3 NA or 63x 1.2 NA objectives in Leica SP 5X
MP confocal laser scanning microscope, CLSM (Leica Microsystems, Heidelberg). Images and
overlays were analyzed in Leica software and exported as TIFF files to CorelDraw for compos-
ite picture. Except for cropping, no image manipulation was used.
In vivo animal experiments
The experiments were performed on male Wistar rats and surgical procedures were similar to
those described earlier for mice [31]. Briefly, animals were anaesthetised with gas isoflurane
and placed on a heated surgical table and maintained at 38o C. The jugular vein was cannulated
and thereafter anaesthesia was maintained with intravenous injection of 2 mg/100 g animal
pentobarbital hourly or as needed. The abdomen was opened, and the proximal end of the bile
duct was ligated. The pancreas and the common pancreatic bile duct was located and cannu-
lated with a polyethylene cannula. The pancreatic juice was collected every 15 minutes. First,
the basal secretion was collected for 30 min, and then secretion was stimulated with constant
intravenous infusion (0.03 ml/min) of secretin (10 pmol/min/animal). Pancreatic juice samples
were collected on ice into weighted vials; secretion rates were calculated and corrected for the
animal weight. Pancreatic juice samples were stored at -20o C for further analysis. At the end of
the experiment, animals were euthanized with pentobarbital overdose and the samples of stom-
ach contents were collected.
Administration of PPI
In acute experiments a single dose of omeprazole and SCH28080 were administrated by the in-
travenous injection through the jugular vein. Omeprazole was dissolved in 40% polyethylene
glycol (PEG 400) [32] and SCH28080 was dissolved in 0.4% methylcellulose-saline suspension
[33]. The doses were chosen according to the previous studies and injected two hours before
collecting pancreatic secretion [33,34]. Omeprazole was given in doses of 5 mg/kg animal and
20 mg/kg animal; SCH28080 was given in 10 mg/kg animal. In matched controls, animals were
injected with appropriate vehicle solutions. In the long-term treatment study, animals were
H+/K+-ATPases in Pancreas
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treated daily by subcutaneous injections of either 5 mg/kg omeprazole or vehicle (40% PEG)
for 30 ± 2 days. The final dose of omeprazole was given a day before the planned operation.
pH and ion concentrations in pancreatic juice
To avoid contaminations from basal and bile secretion for pH and ion measurements, the first
3 samples were excluded from analysis. The pancreatic juice samples were equilibrated with 5%
CO2/air for 30 min and the pH was measured using a glass pH combination electrode (Hanna
Instruments, nr. HI 1083). HCO3
- concentrations were calculated using the Henderson-Hassel-
balch equation. In order to determine whether PPIs were working as predicted in rats, the pH
of stomach contents was also measured, similar to published studies [35]. Stomach contents
were centrifuged to obtain the liquid fraction, which was diluted with distilled water at 1:1 ratio
and the pH was measured. The following analyses were performed on pancreatic juice samples.
Concentrations of Cl- were determined using QuantiChrom Chloride Assay Kit according to
the supplier guidelines (Bioassay Systems). Samples were diluted 10x, transferred to 96 micro-
well plate together with Chloride Assay reagent, absorption at 610 nm was measured and Cl-
concentrations were calculated from the standard curve. Na+ and K+ concentrations were mea-
sured using FLM3 flame photometer (Radiometer Copenhagen). Lactate concentrations were
measured using Lactate Assay kit (Sigma Aldrich) and phosphate concentrations were mea-
sured using QuantiChrom Phosphate Assay Kit (Bioassay Systems), following manufacturer’s
instructions.
Statistics
For real-time PCR, relative quantification (2-ΔΔCt) was used, where Ct denotes the threshold
cycle. The level of transcripts were normalized to house-keeping genes (ΔCt) and then normal-
ized to the expression in Capan-1 cells (ΔΔCt). The protein level was normalized to β-Actin
and then to the Capan-1 protein level. The differences in gene and protein expression were
tested using one way analysis of variance (ANOVA) in Sigma Plot 11 and P<0.05 accepted as
statistically significant. Data from functional measurements (pHi and pancreatic secretion) are
presented as original recordings and summaries showing the mean values ± standard error of
mean, SEM. Control and test pHi measurements were made on the same cell, and n refers to
measurements on different batches of cells. Paired Student´s t test was applied. For ion concen-
tration graphs, raw data was bound into 1 μl/min-kg intervals and each bullet shows the mean
value ± SEM in secretion rates (x-axis) and ion concentrations (y-axis). Statistical analysis on
data obtained from animal experiments was performed using Student0s t-test and ANOVA,
and P< 0.05 was accepted as statistically significant and denoted with asterisks.
Results
Human duct cells express gastric and non-gastric H+/K+-ATPases
Human pancreatic duct adenocarcinoma cell lines Capan-1, CFPAC-1 and PANC-1 are com-
monly used as human pancreatic duct models to study the expression and function of different
ion transporters. Capan-1 and PANC-1 cells express functional CFTR, while CFPAC-1 cells
have F508 deletion in CFTR and thus the protein expression and function are defect. We used
the three cell lines for RT-PCR and results are shown in Fig 1A. We found expression of the
gastric H+/K+-ATPase α subunit (HKα1, 200 bp) and the β subunit (HKβ, 136 bp), as well as
the non-gastric H+/K+-ATPase α subunit (HKα2, 339 bp) in all cell lines. Real time PCR analy-
sis is also shown in Fig 1. Expression levels of transcripts for HKα1, HKβ and HKα2 subunits
among different cell lines were compared with respect to Capan-1 cells.
H+/K+-ATPases in Pancreas
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Fig 1. Expression of H+/K+-ATPases in human pancreatic duct cell lines Capan-1 (CA), CFPAC-1 (CF) and PANC-1 (PA). A:RT-PCR analysis of
gastric H+/K+-ATPase α (HKα1, 200 bp), non-gastric H+/K+-ATPase α (HKα2, 339 bp) and β (HKβ, 136 bp) subunits. Representative gels for at least three
independent experiments. Real time PCR was used to evaluate the relative expression (2-ΔΔCt). The house keeping genes 18S ribosomal RNA (18SrRNA),
β-actin, β glucuronidase (GUSB) and glutaminyl-tRNA synthetase (QARS) were used and expression in Capan-1 cells was set to be 1. The graph shows
data for three experiments (mean±SEM). Significance of expression was tested by one-way ANOVA using the value 2-ΔCt. B:Western blot on cell lysates
from duct cell lines, as well as control tissues—mouse stomach (S) and colon (C). Antibodies against gastric H+/K+-ATPase α subunits (HKα1, Abcam
H+/K+-ATPases in Pancreas
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Expression of gastric and non-gastric H+/K+-ATPases on protein levels was determined in
the three cell lines and with protein extracts from the mouse stomach and colon as positive
controls (Fig 1B). The HKα1 band at ~115 kDa was detected in cell lysates of the three cell
lines and in the stomach. In addition, in Capan-1 cells there was a noticeable band at ~100
kDa. The HKα2 as well as HKβ were also detected in all cell lines. For HKα2, a band at ~100
kDa was detected in colon and in the three duct cell lines. A weaker band at ~115 kDa was also
detectable. Similar results were also observed in the rat pancreas [14]. For the HKβ subunit the
expected band size for the core protein is 35 kDa, and bands at higher sizes indicate glycosy-
lated subunits [36], most prominently glycosylated in the stomach sample. In pancreatic duct
cell lysates, we detected a band with highest intensity at about 40 kDa, similar to the stomach,
and also seen in the rat pancreas [14], and this may indicate lower degree of glycosylation of
the subunit. Additionally, higher bands from 50 to 65 kDa were also observed in all cell lines.
Localization of H+/K+-ATPases in human pancreatic duct cell lines and
human pancreas
The expression and localization of H+/K+-ATPases were further analyzed using immunofluo-
rescence and confocal microscopy. Immunoreactivity for HKα1, HKα2 and HKβ subunits was
observed in the three duct cell lines (data not shown), but here we focus on Capan-1 cells,
which form pancreatic duct epithelia with characteristic ion transporters when grown on per-
meable membranes [4]. Fig 2 shows images of H+/K+-ATPase α1, β or α2 subunits on non-
stimulated cells. For all subunits some immunoreactivity was detected intracellularly, e.g. in
vesicles, but we also observed expression of the pumps on the plasma membranes. The gastric
HKα1 subunit was most strongly expressed on and close to the luminal membranes (Fig 2A).
The gastric HKβ subunit was predominantly found on the luminal side of the epithelium (Fig
2B). The non-gastric HKα2 subunit localized to the luminal, and importantly also to the lateral
membranes of the epithelium (Fig 2C). Whole human pancreas sections showed similar stain-
ing to Capan-1 cells. Fig 3 shows images of ducts of various sizes, and surrounding pancreatic
acini, which did not stain with HK antibodies. The gastric HKα1 localized on or close to the lu-
minal membrane and sub-membrane vesicles in human pancreatic ducts. The gastric HKβ sub-
unit was clearly localized to the luminal membrane, and more diffusely, possibly in vesicles,
proximal to the basal plasma membrane of pancreatic duct cells. The non-gastric HKα2 sub-
unit was detected intracellularly, as well as on the plasma membranes.
Intracellular pH in Capan-1 cells is sensitive to proton pump inhibitors
In order to evaluate the function of H+/K+-ATPases, we applied a method common to study
HCO3
-/H+ transport, i.e. monitoring pHi recovery from an acid load, i.e. the NH4
+/NH3 pre-
pulse technique (Fig 4A and 4C). In order to eliminate the contribution of Na+ and/or HCO3
-
transporters to pHi recovery, we used Na
+- and/or HCO3
—free solutions for bath perfusion.
Capan-1 cells were continuously stimulated with secretin (10–9 M) during the experiments, to
imitate stimulated ductal epithelium [37]. The pHi recovery rate of secretin-stimulated Capan-
1 cells in HCO3
—free physiological buffers was 0.313±0.018 pH units/min, and it was signifi-
cantly reduced to 0.036±0.003 pH units/min in the absence of extracellular Na+ (n = 15). How-
ever, Capan-1 cells were still able to defend pHi changes even without HCO3
- transporters and
EPR12251), non-gastric H+/K+-ATPase α subunits (HKα2, Sigma, HPA039526) and gastric H+/K+-ATPase β subunits (HKβ, Sigma A274) were used.
Loading control was β-actin detected at 43 kDa. All lanes were loaded with 60 μg of protein. Stomach and colon gels were run separately. Lower bargraphs
show expression of the subunits normalized to actin: the bands at 115 kDa (HKα1); 100 kDa (HKα2) and 45 kDa (HKβ) were used. Data is from 3–4
independent experiments and * indicates P<0.05 and ** P<0.001 compared to Capan-1.
doi:10.1371/journal.pone.0126432.g001
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Na+/H+ exchangers. Importantly, this Na+ independent pHi recovery was reduced by H
+/K+-
ATPases inhibitors (Fig 4B and 4D). The gastric H+/K+ pump inhibitor omeprazole inhibited
75% of the Na+ independent pHi recovery (n = 6), while SCH28080 reduced the Na
+ indepen-
dent pHi recovery by 52% (n = 5). In addition, PPIs also reduced pHi recovery when cells were
returned to control Na+ containing buffer (Fig 4 phase III vs. I).
Proton pump inhibitors reduce pancreatic secretory rates
The crucial question to answer now was whether the H+/K+-pumps contribute to pancreatic se-
cretion. Therefore, the following acute and long-term in vivo experiments with proton pump
inhibitors were performed on rats. In the first series of experiments, animals had free access to
food prior to surgery. Omeprazole was given intravenously two hours before pancreatic secre-
tion was induced with secretin. Two doses of omeprazole (5 mg/kg and 20 mg/kg animal) were
tested and the results are shown in Fig 5A. Clearly, 5 mg/kg omeprazole had no significant ef-
fect on pancreatic secretion compared to the vehicle infusion (n = 4 and 6, respectively). High
dose of omeprazole (20 mg/kg animal) had a tendency to reduce pancreatic secretion rate by
about 30% (n = 6), however, statistical significance was not reached with these number of
Fig 2. Immunolocalization of H+/K+-ATPases in Capan-1 cells grown on permeable membranes. A:
The gastric H+/K+-ATPase α subunit (HKα1) was labeled with Calbiochem 119101 (polyclonal, against
HKα1C-terminal) and Alexa 488 (green).B: The gastric H+/K+-ATPase β subunit (HKβ) was detected with
Sigma A-274 (2G11, anti HKβ, monoclonal) and Alexa 488 (green).C: The non-gastric H+/K+-ATPase α
subunit (HKα2) was stained with non-gastric HKα2 antibody (C384-M79) and Alexa 488 (green) Three pairs
of images are shown.D: Example of a control image without primary antibodies but with F-actin marker
(phalloidin Texas red). DAPI was used to stain the nucleus (blue). All bars are 10 μm, and images from at
least 10 independent experiments are presented as both x-y and x-z scans. In x-y scan the left images are
taken mid-way through the monolayer, the right images are taken close to the apical membrane. Dotted lines
in x-y scans indicate where the x-z scan was taken.
doi:10.1371/journal.pone.0126432.g002
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experiments. Pancreatic juice contained relatively high content of secreted proteins, i.e. 29 g/l,
which would indicate enzyme secretion from acini. It is well recognized in pancreatic physiolo-
gy that non-fasted animals have higher fluid and enzyme secretions, due to the endogenous
hormones/transmitters that can activate acinar and duct secretions. Therefore, in all following
experiments animals were fasted overnight. Fig 5B shows the effect of low and high doses of
omeprazole, which now caused significant effects on secretion apparent 30 minutes after stim-
ulation and maintained throughout the experiment. Integrated secretion in the first and second
hour after secretin stimulation were 663±42 and 804±39 µl/h/kg in control animals (n = 4),
and significantly lower in test animals in the same sample periods, i.e. 484±51 (P = 0.018) and
563±68 µl/h/kg (P = 0.014) after low dose omeprazole treatment (n = 4), and 487±58
(P = 0.027) and 581±60 µl/h/kg (P = 0.013) after high dose omeprazole treatment (n = 4). Inter-
estingly, both 5 and 20 mg/kg omeprazole had similar effects, indicating that the maximal ef-
fective dose was reached at 5 mg/kg. This dose of omeprazole also effectively inhibited basal
gastric acid secretion in rats, though 20 mg/kg dose was required for inhibition of pentagastrin
stimulated gastric secretion [34]. In our experiments, we also checked that omeprazole was
working on gastric acid secretion by measuring stomach pH. In control animals pHstomach was
4.16±0.08 and in omeprazole-treated animals it was 5.05±0.13 (n = 15, P = 1.00×10–5).
In order to check the possible contribution of non-gastric H+/K+ pump to pancreatic secre-
tion, the acute effects of SCH28080 were tested. SCH28080 inhibits gastric pump and it has
been reported that in high doses it can also inhibit non-gastric H+/K+ pumps [20,27,28]. In Fig
5C it can be seen that administration of 10 mg/kg SCH28080 resulted in a significant reduction
of secretory rates. During the first hour of secretin stimulation, the secretion was reduced from
739±50 to 438±65 µl/h/kg (P = 0.002) and during the second hour from 1174±92 to 501±117
µl/h/kg (P = 0.0009), comparing control and treatment groups (n = 7; 6). There seems to be
more pronounced inhibition of secretion with SCH28080 than with omeprazole compared to
Fig 3. Immunolocalization of H+/K+-ATPases in sections of human pancreas. A: The gastric H+/K+-
ATPase α subunit (HKα1) was labeled with Calbiochem 119101 (polyclonal, against HKα1C-terminal) (image
1 and 2) and Calbiochem 119102 (polyclonal, against HKα1 N-terminal) and Alexa 488 (green);B: The
gastric H+/K+-ATPase β subunit (HKβ) was stained with Sigma A-274 (2G11, anti HKβ, monoclonal) and
Alexa 488 (green).C: The non-gastric H+/K+-ATPase α subunit (HKα2) was stained with non-gastric HKα2
antibody (C384-M79) and Alexa 488 (green).D: Example of a control image without primary antibodies. DAPI
was used to stain the nucleus (blue). All bars are 25 μm, and images are from 3 independent experiments
and show localization in ducts of various sizes.
doi:10.1371/journal.pone.0126432.g003
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their respective controls. Interestingly, given the dose of inhibitors used in our studies, we
would have expected weaker inhibition by SCH28080, due to higher expected ED50 values.
That is, ED50 of 0.8 mg/kg for omeprazole and 3 mg/kg of SCH28080 was determined for ro-
dent gastric function [33,38].
Above experiments show that acute treatment with both types of blockers (for simplicity de-
noted here PPIs) reduced pancreatic secretion. In order to imitate PPI treatment in humans, it
was relevant to investigate the outcome of long-term omeprazole treatment. Animals were
treated with omeprazole (5 mg/kg) or vehicle for 30 days and subsequently pancreatic secretion
was monitored in anaesthetized animals. The results of the long-term study are represented in
Fig 5D. Comparing control and treatment groups, during the first hour of secretin stimulation
the secretion was reduced from 906±130 to 356±159 µl/h/kg (P = 0.019) and during the second
hour from 876±49 to 403±179 µl/h/kg (P = 0.036) (n = 4; 4). Together, these data on short-
and long-term treatment with PPIs show that they have significant inhibitory effect on pancre-
atic secretion. Do they also have effects on electrolyte composition of pancreatic juice and can
that reveal how the secretion is formed?
Fig 4. Effect of H+/K+-ATPase inhibitors on pHi recovery. A:Representative recording of a pHimeasurement in Capan-1 cells challenged with ammonium
pulse in Na+-containing physiological buffer, then in a Na+-free buffer with or without Na+with omeprazole (10 μM). Dotted lines show the slope of the pHi
recovery from acidosis, i.e. dpH/dt. The pHi recovery was determined when cells were returned to control conditions (periods I, II and III) and in periods with
Na+-free buffer +/- proton inhibitor. B: Summary of recovery rates expressed as dpH/dt upon return to Na+-containing buffer (first three bars) and in Na+-free
buffer (next two bars) (n = 6). C, D: similar representative recording and summary for SCH28080 (10 μM, n = 5). Cells were stimulated with secretin (10–9M)
and buffers were HCO3
—free in order to eliminate contribution of HCO3
- transporters. Bars show paired measurements as means ± SEM. Asterisks indicates
P < 0.05.
doi:10.1371/journal.pone.0126432.g004
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Effect of proton pump inhibitors on pancreatic juice electrolytes
Results of sample analyses for acute and long-term omeprazole experiments compared to con-
trol experiments are given in Fig 6. Fig 6A shows that HCO3
- concentrations depend on
Fig 5. Effects of proton pump inhibitors on pancreatic secretion rates in rats.Controls are represented as blue line and in each graph n is 6, 4, 7 and 4
respectively. A: Effects of 5 mg/kg (red line, n = 4) and 20 mg/kg omeprazole (green line, n = 6) on non-fasted rats. B: Effects of 5 mg/kg (red line, n = 4) and
20 mg/kg omeprazole (green line, n = 4) on fasted rats.C: Effect of 10 mg/kg SCH28080 (yellow line, n = 6) on fasted rats. D: Effects of long term (30 days)
daily administration of 5 mg/kg omeprazole (red line, n = 4). Secretory rates are represented as mean values ± SEM. * indicates P<0.05, ** P<0.01.
doi:10.1371/journal.pone.0126432.g005
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secretory rates. Without inhibitors, in the secretory rate range 10 to 15 µl/min-kg body weight,
HCO3
- concentrations were between 60 to 80 mM.With acute omeprazole treatment, secretion
rates decreased and in the secretory range 7.5 to 12.5 µl/min-kg, HCO3
- concentrations spread
between 45 to 90 mM. Prolonged omeprazole treatment resulted in low secretory rates, below
7 µl/min-kg, and HCO3
- concentrations were around 10 to 20 mM. Also with SCH28080,
HCO3
- concentrations decreased in low secretory rates. Nevertheless, it appears that all data
fall into a HCO3
- excretion curve that follows a characteristic pattern, which is valid for several
animal species and humans [14].
Fig 6. Composition of pancreatic secretions. Relation between pancreatic secretory rates and concentrations of HCO3
- (A), Cl- (B), Na+ (C) and K+ (D).
Data for control experiments are represented blue, acute omeprazole treatment experiments in red and long-term omeprazole treatment experiments in
green. Data for effect of SCH28080 on HCO3
- concentrations are also included and marked in yellow symbols. Data are represented as mean value±SEM for
3–15 samples that were binned in 1 µl/min-kg secretion rate intervals.
doi:10.1371/journal.pone.0126432.g006
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Fig 6B shows that Cl- excretion pattern in control and acute omeprazole samples is inversed
to that for the HCO3
- pattern, as expected [1]. However, in samples from the long-term omep-
razole treated animals, Cl- concentrations were unexpectedly low and independent of secretory
rates. There seemed to be an anion deficit in pancreatic juice, which could have been due to
one or more organic or inorganic anions. We determined lactate in the juice and found that
concentrations were low in both types of experiments: in control samples they were 0.79 ± 0.07
mM (20 samples form 13 animals) and between 0.60 ± 0.04 mM in PPI samples (40 samples
from 18 animals). In addition, we estimated inorganic phosphate concentrations, which were
between 1.5 and 3.5 mM in both control and PPI samples and given pH values in secreted pan-
creatic juice, we estimate that they contribute 2.5 to 6 mequivalents/l.
Fig 6C shows typical Na+ excretory pattern that is independent of secretory rates. Most im-
portantly, Fig 6D shows that K+ excretion has a positive linear correlation with the secretory
rates (r = 0.642 and P<0.0001). Notably, at higher secretion rates pancreatic juice K+ concen-
trations are higher than the plasma values.
Discussion
This is the first study that shows the expression of H+/K+-ATPase α and β subunits in human
pancreatic duct cells on both molecular and functional levels. Furthermore, substantial effect of
proton pump inhibitors on the whole pancreas level confirms that H+/K+-ATPases contribute
to pancreatic secretion, though finding of luminally placed ATPases is surprising. These find-
ings may mark a shift in paradigm in our understanding of acid/base transport in the pancreas.
Various pancreatic duct cells express H+/K+-ATPases subunits
A number of experimental approaches in the present study show that several human duct cell
lines, as well as human pancreatic sections and the whole rat pancreas express gastric and non-
gastric H+/K+-ATPases. First, we observed the expression of both gastric and non-gastric H+/
K+-ATPases on mRNA and protein levels in three different types of human duct cell lines, and
these findings agree with those made on the rat pancreas [14]. The differential expression of
pumps in the three cells lines may reflect the fact that they are cancer cells with different prop-
erties. Nevertheless, Capan-1 cells, which can be grown as monolayers are good models for
transepithelial ion transport in human ducts [4,37], and we used these for further functional
and immunolocalization studies.
The non-gastric pumps have relatively wide distribution and function in H+ and cation ho-
meostasis (see introduction). The targeting of the non-gastric HKα2 subunit to plasma mem-
branes (apical or basolateral) depends on coding motifs and interactions within the subunit,
and possibly association with gastric HKβ or β-subunit of the Na+/K+-ATPase, probably ex-
plains localizations to the apical and/or basolateral membranes of epithelia [24,39–42]. The
gastric pump has been reported for H+ secreting epithelia (see introduction) and its presence in
the HCO3
- secreting epithelium, the pancreas, seemed somewhat peculiar. From a number of
expression studies it is known that specific motifs in the HKα subunit and the glycosylated
HKβ subunit are required for targeting and functional assembly [36,43,44]. Notably, in West-
ern blot analysis of human material, bands of about 40~65 kDa were detected for gastric HKβ
subunit (Fig 1), which might indicate low glycosylation of the protein, also detected in rat pan-
creatic ducts [14]. Nevertheless, we still observe similar localization of the gastric HKβ subunit
with α subunits close to the plasma membrane (Figs 2 and 3). Thus, from molecular consider-
ations one might expect both the gastric and non-gastric H+/K+-ATPase to be functional. The
next question is how their cellular localization explains pancreatic secretion.
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Localization of the H+/K+-ATPases—possible functions on the duct
epithelium
The immunohistochemical data (Figs 2 and 3) shows that the two types of pumps have some-
what different localizations on the pancreatic epithelium. The results for human duct cell lines
in particular show that the H+/K+-pumps (predominantly non-gastric type) are expressed in-
tracellularly and on the lateral membrane of pancreatic ducts. The gastric HKα1 subunits are
detected on the luminal membranes and in adjacent intracellular vesicles, resembling those in
parietal cells. Also gastric HKβ subunits show most distinct placement on or close to the lumi-
nal membranes, indicating that functional gastric H+/K+ ATPase would be formed. This differ-
ential pump distribution is similar to that observed in the rat pancreatic ducts [14]. Although
immunolocalization shows some overlap between gastric and non-gastric pump distribution,
the most interesting question is whether the basolateral and luminal pumps would have
different functions.
Let us address the basolateral pumps. The HCO3
- driven fluid secretion can be achieved by
basolateral HCO3
- transporter loading duct cells with HCO3
- or transport of H+ across the
basolateral membrane and intracellular HCO3
- generation. Thus, the H+/K+-ATPases localized
on the lateral and basal membranes would fulfill HCO3
- secretion by pumping H+ to the baso-
lateral side, leaving HCO3
- for luminal transport. Both the pHi data and pancreatic secretion
data are consistent with above considerations (Figs 4 and 5).
The second observation that H+/K+-pumps (notably the gastric type) are also on the luminal
membrane of pancreatic ducts seems at first perhaps unusual. However, similar pumps
(vacuolar type proton pumps) are found in fish intestine and insect midgut that also secrete
HCO3
—rich fluid [45,46]. Also airway epithelia express proton pumps (and show sensitivity to
vacuolar, gastric and non-gastric pump inhibitors) on the luminal membrane [47–51], though
compared to pancreas, their net HCO3
- secretion is lower and pH of airway surface liquid layer
is< pH 7.4 [52]. The function of luminal proton pumps is unclear.
Let us consider possible functions for the luminal proton pumps. We propose that the lumi-
nal H+/K+-ATPases participate in a protection mechanism in the base secreting epithelium.
One may draw inspiration from the mucus-bicarbonate barrier found in stomach and duode-
num [1], where the barrier provides a near-neutral pH and protection at the epithelial surfaces
[53–55]. In pancreas we have the reverse situation. Human pancreatic duct cells are able to se-
crete up to 140 mMHCO3
- and luminal pH values are above 8 [1,56,57]. Secretion of H+ may
provide protection of luminal epithelial surface. Additionally, several mucin genes have been
identified in pancreatic duct cells and pancreatic mucins would be relevant in epithelial protec-
tion, and altered expression pattern of mucins is one of the important factors in development
and drug resistance in pancreatic cancer [58–60]. In physiological context, we propose that H+
secretion and mucus could provide protection against luminal base, a so called “pancreatic
mucus acid barrier” [1]. In addition, H+/K+-ATPases would serve to recirculate secreted K+
(see below).
Pancreatic secretion—H+/K+-ATPases on integrative level and effect of
proton pump inhibitors
The observation that PPIs and P-CABs inhibit secretin-evoked pancreatic secretion in in vivo
rat studies shows that H+/K+-pumps are in general involved in pancreatic duct secretion. Rat
pancreatic secretion is sensitive to omeprazole, as even the low doses were effective (Fig 5).
Omeprazole, the acid-activated pro-drug, would inhibit the gastric pump, while SCH28080,
which competitively binds to the K+ site, could, most likely, inhibit both gastric and non-gastric
pumps and seems more effective given the dose used in our experiments and published ED50
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values [33,38]. However, clear functional and pharmacological distinction between the two
types of pumps was not possible in our study. Nevertheless, the most important observation is
that PPIs had significant effects. In pHi studies, we acidified the pro-drug and thus the activated
form of omeprazole would be formed. However, in animals, omeprazole would have to be acti-
vated by the acid environment, and the simplest theory is that this would be by the pancreatic
H+/K+-ATPases directly. This might be somewhat analogous to what happens in the stomach,
and thus then provides further evidence for the pumps.
The long-term experiments on rats were performed to find whether omeprazole had cumu-
lative effect on inhibition of pancreatic secretion, or whether animals adjusted to the treatment
and regained normal secretory rates. Clearly, the first was the case and pancreatic secretion was
further reduced by long-term PPI treatment.
In addition to secretory rates, the excretory electrolyte curves indicate underlying secretory
mechanisms. First of all, HCO3
- excretory curve follows predicted relation with secretory rates.
The fact that PPIs do not significantly alter the curve/form indicates that H+/HCO3
- transport
drives the fluid transport and thus secretion. Interesting point to recall here is that rodents,
other animals and humans do show similar HCO3
- excretory curves, indicating similar under-
lying mechanisms [1,14]. The Cl- excretory curves are inversed to those of HCO3
-, which may
be due to Cl-/HCO3
- exchange, or other more complex mechanisms [1], and we cannot explain
anion deficit at low secretory rates.
Regarding the cation excretion, Na+ is not dependent on secretory rates. Similar was
thought to be the case for K+ excretion. However, our data shows that there is a positive rela-
tion between K+ and secretory rate, and moreover that K+ concentrations are higher than plas-
ma values (Fig 6). Similar higher K+ concentrations were also reported in a few early studies
[61–63]. Increased K+ concentrations in pancreatic juice are most likely due to K+ secretion
into duct lumen via luminal K+ channels, such as KCa3.1, KCa1.1 or KCNQ1 [7,64]. These
channels are expressed on luminal membranes and their activation would provide increased
driving force for secretion as already predicted earlier [1,6,7]. In that context, it is reasonable to
envisage that the luminal H+/K+-ATPase could thereby operate and in fact serve to recirculate
or salvage K+ from the lumen, and would explain the observation that H+ and K+ transport
across the luminal membrane is inversely related.
Clinical implications
Proton pump inhibitors (PPIs) are used widely in clinical practice as one of the treatments for
various acid-peptic disorders [65]. As adjuvant therapy PPIs are also prescribed to patients
with pancreatic diseases, such as cystic fibrosis and pancreatitis [66]. Moreover, they are also
suggested as an adjuvant therapy for patients with type 2 diabetes, supposedly because they ele-
vate plasma gastrin and thereby improve insulin secretion [67,68]. Our acute and long-term ex-
periments on rats show that pancreatic secretion is significantly inhibited by PPIs. Therefore,
considering the parallels between H+/K+-ATPases expression in rodent and human pancreatic
epithelia, it would be important to re-consider effect of PPIs on human pancreatic function.
Furthermore, our recent data mining analyses indicate that on the mRNA level ATP4A and
ATP4B are down-regulated in pancreatic cancer [69]. Therefore, the role of H+/K+-ATPases,
alongside with other acid-base transporters, should be considered in potential development of
deregulated acid-base homeostasis in pancreatic ductal adenocarcinoma.
Conclusions
In conclusion, we find that pancreatic ducts express both gastric and non-gastric H+/K+-
ATPases. These pumps are functional in human duct cells and in rat pancreas on the whole
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organ level where they contribute to secretion as demonstrated by PPIs. The laterally and baso-
laterally expressed H+/K+-ATPases would export H+ out of the cell, leaving HCO3
- for luminal
transport and duct secretion. Localization of the H+/K+-ATPases to the luminal membrane is a
change in paradigm, and we propose that they may contribute to the protective buffer zone
and K+ recirculation. Lastly, the solid evidence that we provide for the H+/K+-ATPases in pan-
creas calls for re-evaluation of the use of PPIs as they will not only affect stomach secretion but
also pancreatic secretion—contrary to what may be wished.
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